Macrophage re-programming by JAK inhibitors relies on MAFB
Cell Mol Life Sci. 2024 Mar 25;81(1):152. doi: 10.1007/s00018-024-05196-1.ABSTRACTMonocyte-derived macrophages play a key pathogenic role in inflammatory diseases. In the case of rheumatoid arthritis (RA), the presence of specific synovial tissue-infiltrating macrophage subsets is associated with either active disease or inflammation resolution. JAK inhibitors (JAKi) are the first targeted synthetic disease-modifying antirheumatic drugs (tsDMARD) approved for treatment of RA with comparable efficacy to biologics. However, the effects of JAKi on macrophage specification and differentiation are currently unknown. We have analyzed the transcriptional and functional effects of JAKi on human peripheral blood monocyte subsets from RA patients and on the differentiation of monocyte-derived macrophages promoted by granulocyte-macrophage colony-stimulating factor (GM-CSF), a factor that drives the development and pathogenesis of RA. We now report that JAKi Upadacitinib restores the balance of peripheral blood monocyte subsets in RA patients and skewed macrophages towards the acquisition of an anti-inflammatory transcriptional and functional profile in a dose-dependent manner. Upadacitinib-treated macrophages showed a strong positive enrichment of the genes that define synovial macrophages associated to homeostasis/inflammation resolution. Specifically, Upadacitinib-treated macrophages exhibited significantly elevated expression of MAFB and MAFB-regulated genes, elevated inhibitory pho...
Source: Cellular and Molecular Life Sciences : CMLS - Category: Cytology Authors: Baltasar L ópez-Navarro Miriam Sim ón-Fuentes Israel R íos Mar ía Teresa Schiaffino Alicia Sanchez M ónica Torres-Torresano Alicia Nieto-Valle Isabel Castrej ón Amaya Puig-Kr öger Source Type: research
More News: Arthritis | Cytology | Genetics | Israel Health | Middle East Health | Molecular Biology | Rheumatoid Arthritis | Rheumatology